← All trials
NCT05049902
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 21, 2021
- Primary completion
- Sep 30, 2023
- Completion date
- Oct 31, 2023
- First posted
- Sep 20, 2021
- Last posted
- Oct 19, 2021
- Enrollment
- 1300
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Shandong UniversityLead sponsor
- Nanjing Medical UniversityCollaborator
- Shandong UniversityOverall official - principal investigator
- Shandong UniversityReponsible party - principal investigator
- PKUcare luzhong hospitalCollaborator
- Heze Municipal 3rd people's hospitalCollaborator
- Maternity and Child Care Health Center of DezhouCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.